ARQT News and Press, Arcutis Biotherapeutics Inc. From 12/05/22

ARQ-255 is a topical janus kinase (JAK) inhibitor therapy specifically designed as a potential treatment for alopecia areata Proprietary Deep Dermal Drug Delivery (4D) formulation designed to deliver drug deep into the skin to the base of the hair follicle where key alopecia areata inflammati...

MyHealthTeam and Arcutis Biotherapeutics Launch New Social Network for People Living with Seborrheic Dermatitis PR Newswire MySebDermTeam provides trusted connection, information, and support to accelerate diagnosis and treatment SAN FRANCISCO , Dec. 1, 2022 /PRN...

Newly published phase 2b trial data show those treated with roflumilast cream had significantly greater improvements in itch compared to those treated with vehicle by Week 2 as assessed by the Worst Itch Numeric Rating Scale (WI-NRS) and Psoriasis Symptom Diary (PSD) Among a s...

Report highlights efforts to advance diversity and inclusion, access to medicine, sustainable business practices, and governance WESTLAKE VILLAGE, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focuse...

ZORYVE is now on formulary for one of the top pharmacy benefit managers serving commercially insured patients, effective November 18, 2022 ZORYVE is a once-daily non-steroidal cream and the first and only topical PDE4 inhibitor approved for use in plaque psoriasis, including all...

Study met the primary endpoint and all secondary endpoints For the primary endpoint, 32.0% of individuals treated with roflumilast cream 0.15% achieved Investigator Global Assessment (IGA) Success compared to 15.2% of individuals treated with vehicle (P<0.0001) 43.2% of indiv...

Arcutis Biotherapeutics ( NASDAQ: ARQT ) added ~6% pre-market Tuesday after announcing that its investigational therapy for atopic dermatitis (AD) roflumilast met the primary endpoint and all secondary endpoints in a pivotal Phase 3 trial. The double-blind, vehicle-contr...

Study met the primary endpoint and all secondary endpoints For the primary endpoint, 32.0% of individuals treated with roflumilast cream 0.15% achieved Investigator Global Assessment (IGA) Success compared to 15.2% of individuals treated with vehicle (P<0.0001) 43.2% of indiv...

The following slide deck was published by Arcutis Biotherapeutics, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Arcutis Biotherapeutics, Inc. 2022 Q3 - Results - Earnings Call Presentation

Arcutis Biotherapeutics, Inc. (ARQT) Q3 2022 Earnings Conference Call November 08, 2022, 17:00 ET Company Participants Eric McIntyre - Head, IR Todd Watanabe - President, CEO & Director Kenneth Lock - Chief Commercial Officer Patrick Burnett - SVP & C...